WO2006019841A3 - S - Google Patents

S Download PDF

Info

Publication number
WO2006019841A3
WO2006019841A3 PCT/US2005/024893 US2005024893W WO2006019841A3 WO 2006019841 A3 WO2006019841 A3 WO 2006019841A3 US 2005024893 W US2005024893 W US 2005024893W WO 2006019841 A3 WO2006019841 A3 WO 2006019841A3
Authority
WO
WIPO (PCT)
Prior art keywords
activators
treatment
egr
viral infections
infected
Prior art date
Application number
PCT/US2005/024893
Other languages
English (en)
Other versions
WO2006019841A2 (fr
Inventor
Steven Zeichner
Vyjayanthi Krishnan
Original Assignee
Us Government
Steven Zeichner
Vyjayanthi Krishnan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Government, Steven Zeichner, Vyjayanthi Krishnan filed Critical Us Government
Publication of WO2006019841A2 publication Critical patent/WO2006019841A2/fr
Publication of WO2006019841A3 publication Critical patent/WO2006019841A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un traitement de cellules ou d'humains porteurs d'un virus ou infectés par un virus pouvant provoquer une maladie immunodéficiente. Le traitement de l'invention fait appel à des composés particuliers, notamment des activateurs Egr 1.
PCT/US2005/024893 2004-07-13 2005-07-13 S WO2006019841A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58801304P 2004-07-13 2004-07-13
US60/588,013 2004-07-13

Publications (2)

Publication Number Publication Date
WO2006019841A2 WO2006019841A2 (fr) 2006-02-23
WO2006019841A3 true WO2006019841A3 (fr) 2007-02-22

Family

ID=35907884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/024893 WO2006019841A2 (fr) 2004-07-13 2005-07-13 S

Country Status (1)

Country Link
WO (1) WO2006019841A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049773A1 (fr) 2011-09-30 2013-04-04 Vanderbilt University Thérapies antivirales avec des inhibiteurs de phospholipase d
US20140163055A1 (en) * 2012-12-11 2014-06-12 Vanderbilt University Methods and compositions of treating hiv infection
WO2015114584A1 (fr) * 2014-01-31 2015-08-06 Ghimas S.P.A. Polydatine pour le traitement du vih chez des patients
US20230119141A1 (en) * 2021-10-19 2023-04-20 Phyto Tech Corp. Uses of taxifolin for respiratory health
WO2023235826A2 (fr) * 2022-06-02 2023-12-07 The Regents Of The University Ofcolorado A Body Corporate Procédés de modulation d'endonucléase g à l'aide de resvératrol et de ses dérivés

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4340438A1 (de) * 1993-11-27 1995-06-01 Erwin Backhaus Mittel zur Inaktivierung von Retroviren
WO1999056737A1 (fr) * 1998-05-05 1999-11-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonistes des ligands du recepteur des arylhydrocarbures
WO2001012228A2 (fr) * 1999-08-13 2001-02-22 University Of Maryland Biotechnology Institute Compositions pour le traitement des infections virales, et procedes correspondants
WO2003002126A1 (fr) * 2001-06-28 2003-01-09 University Of Pretoria Agent antiretroviral en combinaison avec du polyphenol de the pour le traitement d'infections virales
WO2003054160A2 (fr) * 2001-12-19 2003-07-03 The Regents Of The University Of California Lignees cellulaires a virus de l'immunodeficience latent, et procedes d'utilisation
WO2006017346A1 (fr) * 2004-07-13 2006-02-16 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH A ND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER Traitement d'infections virales au moyen d'inhibiteurs de proteasome

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4340438A1 (de) * 1993-11-27 1995-06-01 Erwin Backhaus Mittel zur Inaktivierung von Retroviren
WO1999056737A1 (fr) * 1998-05-05 1999-11-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonistes des ligands du recepteur des arylhydrocarbures
WO2001012228A2 (fr) * 1999-08-13 2001-02-22 University Of Maryland Biotechnology Institute Compositions pour le traitement des infections virales, et procedes correspondants
WO2003002126A1 (fr) * 2001-06-28 2003-01-09 University Of Pretoria Agent antiretroviral en combinaison avec du polyphenol de the pour le traitement d'infections virales
WO2003054160A2 (fr) * 2001-12-19 2003-07-03 The Regents Of The University Of California Lignees cellulaires a virus de l'immunodeficience latent, et procedes d'utilisation
WO2006017346A1 (fr) * 2004-07-13 2006-02-16 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH A ND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER Traitement d'infections virales au moyen d'inhibiteurs de proteasome

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DELLA RAGIONE FULVIO ET AL: "Antioxidants induce different phenotypes by a distinct modulation of signal transduction.", FEBS LETTERS, vol. 532, no. 3, 18 December 2002 (2002-12-18), pages 289 - 294, XP004398419, ISSN: 0014-5793 *
HEREDIA, ALONSO ET AL: "Synergistic inhibition of HIV -1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol", JAIDS, JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES , 25(3), 246-255 CODEN: JJASFJ, 2000, XP000982355 *
KRISHNAN VYJAYANTHI ET AL: "Host cell gene expression during human immunodeficiency virus type I latency and reactivation and effects of targeting genes that are differentially expressed in viral latency", JOURNAL OF VIROLOGY, vol. 78, no. 17, September 2004 (2004-09-01), pages 9458 - 9473, XP008067579, ISSN: 0022-538X *
MAHMOOD, N. ET AL: "Constituents of Cuscuta reflexa are anti- HIV agents", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY , 8(1), 70-74 CODEN: ACCHEH; ISSN: 0956-3202, 1997, XP008067586 *
RABBI MOHAMMED F ET AL: "Interleukin-10 enhances tumor necrosis factor-alpha activation of HIV-1 transcription in latently infected T cells", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, vol. 19, no. 4, 1 December 1998 (1998-12-01), pages 321 - 331, XP008067583, ISSN: 1077-9450 *
VAN 'T WOUT ANGELIQUE B ET AL: "Cellular gene expression upon human immunodeficiency virus type 1 infection of CD4+-T-cell lines.", JOURNAL OF VIROLOGY, vol. 77, no. 2, January 2003 (2003-01-01), pages 1392 - 1402, XP002396149, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2006019841A2 (fr) 2006-02-23

Similar Documents

Publication Publication Date Title
WO2008127364A3 (fr) Composés antiviraux et utilisation de ceux-ci
WO2004112687A3 (fr) Compositions et methodes antivirales
WO2006033995A3 (fr) Thiazolidine-4-ones possedant une activite antihepatite b
WO2007084413A3 (fr) Procedes de traitement de l’hepatite c
WO2007084435A8 (fr) Procedes de traitement de l'hepatite c
WO2007070600A3 (fr) Composés antiviraux n-(noyau aromatique à 5 chaînons) amido
WO2004060308A3 (fr) Thiosemicarbazones antiviraux et immunostimulants
WO2008115281A3 (fr) Composés de traitement d'infections virales
WO2007022073A3 (fr) Nouveaux dérivés de 2’-c-méthyl- et de 4’-c-méthyl-nucléosides
PL378354A1 (pl) Analogi nukleozydów przeciwwirusowych i sposoby leczenia zakażeń wirusowych, zwłaszcza zakażeń wirusem HIV
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
WO2006027628A3 (fr) Derives de naphtalimide en tant qu'agents antiviraux
WO2008003149A3 (fr) Ptéridines substituées pour le traitement et la prévention d'infections virales
WO2004011478A3 (fr) Nucleosides d de 7-deaza antiviraux et leurs utilisations
WO2003093290A3 (fr) Derives nucleosidiques destines au traitement de l'infection par le virus de l'hepatite c
WO2006110831A3 (fr) Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine
WO2006124861A3 (fr) Composes de benzofuranne
WO2009094191A3 (fr) Méthodes de traitement d’infections virales
EP2234977A4 (fr) Inhibiteurs de polymérase virale
WO2006131936A3 (fr) Vaccin du virus de l'hepatite c
WO2008073982A3 (fr) Composés de 5,6-dihydro-1h-pyridine-2-one
WO2007065007A3 (fr) Traitement d'infections virales
WO2007002639A3 (fr) Agents anti-hepacivirus non-nucleoside et utilisations de ceux-ci
WO2006019841A3 (fr) S
AU2001232267A1 (en) Remedies for hepatitis c

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase